After 11 years in pharma commercial strategy and event programming, I’ve sat through thousands of debriefs. The most common sentiment I hear? “The conference was great, we met a lot of people, but I’m not sure what happens next.”
If you don’t know what happens next before you even pack your bag, you are effectively paying thousands of dollars for a branded lanyard and a box lunch. For a biotech business development (BD) team, the three-week mark before a major event like BIO isn't the time to start browsing the agenda—it is the point of no return for your actual return on investment (ROI).
In this industry, we suffer from “event FOMO.” We call every gathering a “must-attend,” when in reality, most are glorified cocktail hours. Let’s strip away the hype and focus on the mechanics of building a conference portfolio that actually moves the needle on licensing and commercial strategy.
The Summer Anchor: Why BIO Demands Discipline
BIO is your summer anchor. It is the largest venue for partnering outreach, but it is also the easiest place to lose focus. By three weeks out, your licensing targets list should be finalized, segmented, and being actively engaged via the BIO Partnering platform.
If you are still “browsing” companies in the platform at this stage, you’re too late. The system should be used as a precision instrument, not a search engine. Your primary goal at BIO is to secure high-intent meetings with decision-makers, not to bump into people in the hallway.
The 3-Week Checklist for BIO Partnering
- Filter by Mandate: Sort your target list by therapeutic area alignment AND stage of development. Do not waste a meeting request on a firm that is currently divesting your specific modality. The 48-Hour Response Rule: If you haven’t sent your first round of meeting requests BIO, start today. Send them by end-of-day tomorrow. Any request sent within two weeks of the event is likely to be ignored or accepted only because the recipient has an open gap in their calendar. Internal Alignment: Define the "Ask." Are you looking for a co-development partner, an out-licensing deal, or simply a strategic landscape check? If your team members can't articulate the "Ask" in one sentence, cancel the meeting.
Curating Your Portfolio: Beyond the Hype
A smart commercial strategy treats conferences as tools in a kit. You aren't going to BIO for the same reason you go to Fierce Pharma Week or The Health Management Academy (THMA) forums. You need to distinguish between networking (fluff) and strategic progression (outcomes).
Event Strategic Outcome Primary Focus BIO Pipeline validation & licensing Partnering and deal-flow Fierce Pharma Week Commercial execution Marketing strategy & competitive intelligence THMA Forums Formulary reality Payer access & system adoptionCommercial Execution: Why Fierce Pharma Week Matters
While BIO is for the "what" (the science and the asset), Fierce Pharma Week is for the "how" (the market launch). If you are in the pre-commercial phase, this is where you go to test your messaging against your competitors' latest plays.
Most teams make the mistake of sending only marketing folks to Fierce. That’s a mistake. You need your CI (Competitive Intelligence) lead and your BD lead there. Use this time to pressure-test your value proposition. If you can’t describe your commercial differentiation in a way that makes a skeptical room of peers nod, your launch plan is likely too abstract. Use these events to listen to how your competitors are talking about their upcoming data drops.
The Reality Check: THMA and the Formulary Wall
This is where the rubber meets the road. I often see biotech teams get so obsessed with clinical endpoints that they forget the only opinion that matters for long-term commercial success: the one held by health system leadership and pharmacy benefit managers (PBMs).
The Health Management Academy (THMA) forums serve a very specific, utilitarian purpose: they expose you to the messy, non-clinical reality of health system adoption. You are not going there to pitch; you are going there to understand the "formulary wall."
Why does this matter for BD? Because a licensing partner will eventually ask you: "What is your pathway to broad access?" If you can answer that with insights gained from THMA—such as how major health systems are currently evaluating budget impact for your class of therapy—you are miles ahead of the competition. It makes your asset infinitely more attractive to a partner who doesn't want to figure out the access puzzle on their own.
Meetings That Look Big But Do Nothing
I keep a running list of "meetings that look big but do nothing for adoption." It’s my way of staying grounded. If you are attending a conference, avoid these traps:
The "Executive Panel" Trap: Attending a session where a high-level executive is giving a canned speech. You will learn nothing you couldn't read in a press release. The "Vendor-Heavy" Social Hour: If the ratio of service providers to potential partners is greater than 3:1, leave. You are being sold to, not partnering. The "Broad Outreach" Breakfast: Avoid sessions where you are essentially "attending" alongside 500 other people. Real business happens in the 1-on-1s, not the ballroom.The Bottom Line: Precision Over Presence
The biggest mistake in pharma commercial strategy is thinking that "being there" is enough. It Fierce Pharma Week 2026 isn't. In fact, being everywhere often means you aren't focused on anywhere.
Three weeks out from BIO, your focus should be entirely on execution. Audit your licensing targets list. Scrub your partnering outreach for clarity and brevity. If you are a BD lead, your calendar should already be filling up with high-quality, high-intent meetings.
Stop focusing on the event brand. Start focusing on the outcome. If you can’t map a meeting to a specific business goal, don’t take the meeting. If you can’t map a conference to a specific strategic milestone, don’t attend. Your company’s capital—and your limited time—is better spent elsewhere.
Now, go check your BIO Partnering platform. If those requests haven't been sent, stop reading this and get to work.